WO2021039592A1 - Procédé d'aide à la découverte de médicament, dispositif d'aide à la découverte de médicament et programme - Google Patents

Procédé d'aide à la découverte de médicament, dispositif d'aide à la découverte de médicament et programme Download PDF

Info

Publication number
WO2021039592A1
WO2021039592A1 PCT/JP2020/031480 JP2020031480W WO2021039592A1 WO 2021039592 A1 WO2021039592 A1 WO 2021039592A1 JP 2020031480 W JP2020031480 W JP 2020031480W WO 2021039592 A1 WO2021039592 A1 WO 2021039592A1
Authority
WO
WIPO (PCT)
Prior art keywords
target
information
drug discovery
threshold value
fluorescent
Prior art date
Application number
PCT/JP2020/031480
Other languages
English (en)
Japanese (ja)
Inventor
高橋　優
義一 栗原
祐輝 三宅
Original Assignee
コニカミノルタ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コニカミノルタ株式会社 filed Critical コニカミノルタ株式会社
Priority to JP2021542816A priority Critical patent/JPWO2021039592A1/ja
Publication of WO2021039592A1 publication Critical patent/WO2021039592A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M1/00—Apparatus for enzymology or microbiology
    • C12M1/34—Measuring or testing with condition measuring or sensing means, e.g. colony counters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Definitions

  • the present invention relates to a drug discovery support method, a drug discovery support device, and a program.
  • An object of the present invention is to provide a drug discovery support method, a drug discovery support device, and a program capable of quickly and accurately determining the sensitivity of a drug and a suitable biological part.
  • the drug discovery support method of the present invention is used.
  • the drug discovery support device of the present invention is An acquisition means for acquiring expression information of a target part in a plurality of biological parts and a fluorescently labeled target biological substance of the target part to be compared with the target part.
  • a display control means for displaying the list information obtained by digitizing the expression information of each part acquired by the acquisition means and displaying the list information, and the threshold value information indicating a predetermined threshold value on the display unit. To be equipped.
  • the program of the present invention Computer, An acquisition means for acquiring expression information of a target part in a plurality of biological parts and a fluorescently labeled target biological substance of the target part to be compared with the target part. A display control means for displaying on the display unit the list information obtained by digitizing the expression information of each part acquired by the acquisition means and displaying the list information and the threshold value information indicating a predetermined threshold value. It is a program that functions as.
  • FIG. 1 It is a figure which shows the schematic structure of the drug discovery support system which concerns on this invention. It is a block diagram which shows the functional structure of the information acquisition apparatus of FIG. It is a figure which shows an example of evaluation support information. It is a figure for demonstrating evaluation support information. It is a figure which shows an example of evaluation support information.
  • FIG. 1 shows an overall configuration example of a drug discovery support system 100 that executes the drug discovery support method according to the present invention.
  • the drug discovery support system 100 acquires a microscopic image of a tissue sample stained with a predetermined staining reagent, and analyzes the acquired microscopic image to quantitatively express the expression of a specific biological substance in the tissue sample to be observed. It is a system that can output the feature amount represented by.
  • the drug discovery support system 100 is configured by connecting a microscope image acquisition device 1A and an information acquisition device 2A as a drug discovery support device so as to be able to transmit and receive data via an interface such as a cable 3A.
  • the connection method between the microscope image acquisition device 1A and the information acquisition device 2A is not particularly limited.
  • the microscope image acquisition device 1A and the information acquisition device 2A may be connected by a LAN (Local Area Network) or may be wirelessly connected.
  • LAN Local Area Network
  • the microscope image acquisition device 1A is a known optical microscope with a camera, which acquires a microscope image of a tissue sample on a slide placed on a slide fixing stage and transmits it to the information acquisition device 2A.
  • the microscope image acquisition device 1A is configured to include an irradiation means, an imaging means, an imaging means, a communication I / F, and the like.
  • the irradiation means is composed of a light source, a filter, and the like, and irradiates a tissue sample on the slide placed on the slide fixing stage with light.
  • the imaging means is composed of an eyepiece, an objective lens, or the like, and forms a transmitted light, a reflected light, or a fluorescence emitted from a tissue sample on a slide by the irradiated light.
  • the imaging means is a microscope-installed camera equipped with a CCD (Charge Coupled Device) sensor or the like, and images an image formed on an imaging surface by the imaging means to generate digital image data of a microscope image.
  • the communication I / F transmits the image data of the generated microscope image to the information acquisition device 2A.
  • the microscope image acquisition device 1A includes a bright field unit in which an irradiation means and an imaging means suitable for bright field observation are combined, and a fluorescence unit in which an irradiation means and an imaging means suitable for fluorescence observation are combined. It is possible to switch between bright field and fluorescence by switching the unit.
  • the microscope image acquisition device 1A is not limited to a microscope with a camera, and is, for example, a virtual microscope slide creation device (for example, a special microscope image acquisition device) that scans a slide on a slide fixing stage of a microscope to acquire a microscope image of the entire tissue specimen. (See Table 2002-514319) and the like may be used. According to the virtual microscope slide creating device, it is possible to acquire image data in which the entire image of the tissue sample on the slide can be viewed at once on the display unit.
  • a virtual microscope slide creation device for example, a special microscope image acquisition device
  • the information acquisition device 2A analyzes the microscope image transmitted from the microscope image acquisition device 1A.
  • FIG. 2 shows an example of the functional configuration of the information acquisition device 2A.
  • the information acquisition device 2A is configured to include a control unit 21, an operation unit 22, a display unit 23, a communication I / F 24, a storage unit 25, and the like, and each unit is connected via a bus 26. There is.
  • the control unit 21 is configured to include a CPU (Central Processing Unit), a RAM (Random Access Memory), etc., executes various processes in cooperation with various programs stored in the storage unit 25, and executes various processes to obtain information acquisition device 2A. Controls the operation of.
  • a CPU Central Processing Unit
  • RAM Random Access Memory
  • the operation unit 22 is configured to include a keyboard equipped with character input keys, number input keys, various function keys, and a pointing device such as a mouse, and a key press signal operated by the keyboard and an operation signal by the mouse. Is output to the control unit 21 as an input signal.
  • the display unit 23 is configured to include, for example, a monitor such as a CRT (Cathode Ray Tube) or an LCD (Liquid Crystal Display), and displays various screens according to instructions of display signals input from the control unit 21.
  • a monitor such as a CRT (Cathode Ray Tube) or an LCD (Liquid Crystal Display)
  • LCD Liquid Crystal Display
  • the communication I / F 24 is an interface for transmitting and receiving data to and from an external device such as the microscope image acquisition device 1A, and inputs a fluorescent image captured by the microscope image acquisition device 1A to the information acquisition device 2A. Act as a means for.
  • the storage unit 25 is composed of, for example, an HDD (Hard Disk Drive), a semiconductor non-volatile memory, or the like. As described above, various programs, various data, and the like are stored in the storage unit 25.
  • the information acquisition device 2A may be provided with a LAN adapter, a router, or the like, and may be connected to an external device via a communication network such as a LAN.
  • the drug discovery support methods according to this embodiment are mainly 1. 2. The process of staining sections of multiple organs (living parts) using a staining reagent. 2. The step of detecting the domain of the biological substance from the stained section and 3. It has a step of evaluating the expression level of the domain of the detected biological substance.
  • fluorescent nanoparticles can be used as a staining reagent.
  • Fluorescent nanoparticles are nano-sized particles that emit fluorescence when irradiated with excitation light, and are particles capable of emitting fluorescence having sufficient intensity to represent a target biological substance as a bright spot one by one.
  • fluorescent nanoparticles preferably fluorescent substance integrated nanoparticles (PID) are used.
  • a biological substance recognition site that recognizes one domain is bound to one of the nanoparticles, and a predetermined fluorescent substance is contained therein.
  • a fluorescent substance having a biological substance recognition site that recognizes a domain different from the biological substance recognition site of one nanoparticle is bound to the other nanoparticle, and has a fluorescence wavelength different from that of the fluorescent substance of one nanoparticle. It is included. That is, each nanoparticles contains biomaterial recognition sites that are different from each other and fluorescent substances having different fluorescence wavelengths. Therefore, different domains of the same protein can be clearly distinguished and stained due to the difference in fluorescence wavelength caused by the fluorescent substance.
  • three or more types of nanoparticles may be used to detect three or more types of domains. Details of the types and characteristics of fluorescent substances and methods for detecting biological substances are as follows.
  • Target biomaterial is a substance that is subject to immunohistochemical staining using a fluorescent label, mainly for detection or quantification from the viewpoint of pathological diagnosis, and is expressed in a tissue section. It is a biological substance.
  • target biological substance applicable to the present embodiment examples include biological substances that can be used as biomarkers such as proteins (antigens) and mRNA. Specific examples include, but are not limited to, PD-L1, HER2, TIM-3, and the like.
  • Fluorescent substance-accumulated nanoparticles are based on particles made of organic substances or inorganic substances, and a plurality of fluorescent substances (for example, fluorescent organic dyes and quantum dots described later) are contained therein. Nano-sized particles having a structure that is and / or is adsorbed on the surface thereof. As the fluorescent substance-accumulated nanoparticles, it is preferable that the matrix and the fluorescent substance have substituents or sites having opposite charges and electrostatically interact with each other. As the fluorescent substance-accumulated nanoparticles, fluorescent dye-accumulated nanoparticles, quantum dot-accumulated nanoparticles, and the like are used.
  • fluorescent substance used in the dyeing reagent for acquiring a fluorescent image examples include a fluorescent organic dye and quantum dots (semiconductor particles). When excited by ultraviolet-near-infrared light having a wavelength in the range of 200 to 700 nm, it is preferable to exhibit visible to near-infrared light having a wavelength in the range of 400 to 1000 nm.
  • Fluorescein dye molecules Fluorescein dye molecules, rhodamine dye molecules, Alexa Fluor (Invigen) dye molecules, BODIPY (Invigen) dye molecules, cascade dye molecules, coumarin dye molecules, and eodin dyes
  • examples thereof include molecules, NBD-based dye molecules, pyrene-based dye molecules, Texas Red-based dye molecules, cyanine-based dye molecules, and the like.
  • Quantum dots include group II-VI compounds, group III-V compounds, or group IV elements as components ("group II-VI quantum dots”, “group III-V quantum dots”, and “group III-V quantum dots, respectively”. Either of "Group IV quantum dots") can be used. It may be used alone or in a mixture of a plurality of types.
  • Specific examples include, but are not limited to, CdSe, CdS, CdTe, ZnSe, ZnS, ZnTe, InP, InN, InAs, InGaP, GaP, GaAs, Si, and Ge.
  • a quantum dot having the above quantum dot as a core and a shell provided on the core.
  • the core is CdSe and the shell is ZnS
  • CdSe / ZnS when the core is CdSe and the shell is ZnS, it is described as CdSe / ZnS.
  • CdSe / ZnS, CdS / ZnS, InP / ZnS, InGaP / ZnS, Si / SiO 2 , Si / ZnS, Ge / GeO 2 , Ge / ZnS and the like can be used, but are not limited thereto.
  • the quantum dots may be surface-treated with an organic polymer or the like.
  • CdSe / ZnS having a surface carboxy group manufactured by Invitrogen
  • CdSe / ZnS having a surface amino group manufactured by Invitrogen
  • the fluorescent substance to be accumulated in the fluorescent substance-accumulated nanoparticles in addition to the fluorescent organic dye and the quantum dot as described above, for example, Y 2 O 3 , Zn 2 SiO 4, etc. are used as the parent body, and Mn 2+, Eu 3+, etc. are activated. Examples thereof include a "long afterglow phosphor" as an agent.
  • the organic substances are resins generally classified as thermosetting resins such as melamine resin, urea resin, aniline resin, guanamine resin, phenol resin, xylene resin, and furan resin; styrene.
  • Resins generally classified as thermoplastic resins such as resins, acrylic resins, acrylonitrile resins, AS resins (acrylonitrile-styrene copolymers), ASA resins (acrylonitrile-styrene-methyl acrylate copolymers); polylactic acid, etc.
  • Other resins; polysaccharides can be exemplified.
  • the inorganic substance in the mother body include silica and glass.
  • Quantum dot integrated nanoparticles have a structure in which the quantum dots are contained in the mother body and / or are adsorbed on the surface thereof. When the quantum dots are contained in the mother body, the quantum dots need only be dispersed inside the mother body, and may or may not be chemically bonded to the mother body itself.
  • the fluorescent dye-accumulated nanoparticles have a structure in which the fluorescent organic dye is contained in the mother body and / or is adsorbed on the surface thereof.
  • the fluorescent organic dye may or may not be chemically bonded to the mother body itself as long as it is dispersed inside the mother body.
  • fluorescent substance integrated nanoparticles can be produced according to a known method.
  • the fluorescent substance-encapsulating silica particles containing silica as a base and a fluorescent substance contained therein are fluorescent substances such as quantum dots and fluorescent organic dyes, and a silica precursor such as tetraethoxysilane. It can be prepared by dropping a solution in which and is dissolved in a solution in which ethanol and ammonia are dissolved and hydrolyzing the silica precursor.
  • a solution of those resins or a dispersion of fine particles is prepared in advance. It can be produced by adding a fluorescent substance such as a quantum dot or a fluorescent organic dye to the mixture and stirring the mixture. Alternatively, the fluorescent substance-accumulated resin particles can be produced by advancing the polymerization reaction after adding the fluorescent substance to the solution of the resin raw material.
  • thermosetting resin such as a melamine resin
  • the raw material of the resin (monomer or oligomer or prepolymer, for example, methylol melamine which is a condensate of melamine and formaldehyde) and a fluorescent organic dye are used.
  • Fluorescent dye-accumulated resin particles can be produced by heating a reaction mixture containing a surfactant and a polymerization reaction accelerator (acid or the like), and proceeding the polymerization reaction by an emulsion polymerization method.
  • the raw material of the resin and the fluorescent organic dye (as the raw material monomer of the resin, the organic fluorescent dye is previously bonded by a covalent bond or the like).
  • the reaction mixture containing the above-mentioned monomer (may be used) and a polymerization initiator (benzoyl peroxide, azobisisobutyronitrile, etc.) is heated, and the polymerization reaction is allowed to proceed by a radical polymerization method or an ionic polymerization method. Therefore, the fluorescent dye-accumulated resin particles can be produced.
  • the average particle size of the fluorescent substance-accumulated nanoparticles used in the present embodiment is not particularly limited, but those having a large particle size have difficulty in accessing the antigen, and the particle size is small and the brightness value is low. Since the signal of the nanoparticles accumulating fluorescent substances is buried in background noise (camera noise and autofluorescence of cells), those having a wavelength of about 20 to 500 nm are preferable.
  • the average particle size is determined by taking an electron micrograph using a scanning electron microscope (SEM), measuring the cross-sectional area of a sufficient number of particles, and using each measured value as the area of a circle. Asked as. In the present application, the arithmetic mean of the particle sizes of 1000 particles is taken as the average particle size. The coefficient of variation was also a value calculated from the particle size distribution of 1000 particles.
  • SEM scanning electron microscope
  • an antibody that specifically recognizes and binds to a protein as a target biological substance as an antigen can be used.
  • an antibody that recognizes and binds to a specific domain of the same target biological substance (protein) is used as the primary antibody.
  • PD-L1 when PD-L1 is the target biological substance, "SP263”, “SP142” (all manufactured by Ventana), and “E1L3N” (Cell Signaling Technology) are used as anti-PD-L1 antibodies that can recognize the intracellular domain.
  • As an anti-PD-L1 antibody that can recognize the extracellular domain "22c3" (manufactured by Dako) and “28-8" (manufactured by Abcam) can be used.
  • HER2 When HER2 is used as the target biological substance, "4B5" (manufactured by Ventana), "CB11” (manufactured by BioGenex), and extracellular domain can be recognized as anti-HER2 antibodies capable of recognizing the intracellular domain.
  • SV2-61 ⁇ manufactured by Nichirei Bioscience
  • TIM-3 used as the target biological substance
  • F38-2E2 "RMT3-23” (all manufactured by BioLegend)
  • MM0936 used as anti-TIM-3 antibodies that can recognize the intracellular domain
  • 14S23 "RM0135-6F46” (both manufactured by Abcam), and "344823” (manufactured by R & D Systems) can be used as an anti-TIM-3 antibody capable of recognizing the extracellular domain.
  • the primary antibody may be an antibody fragment or derivative instead of a natural full-length antibody as long as it has the ability to specifically recognize and bind to a specific biological substance (antigen). That is, the term "antibody” as used herein refers to not only full-length antibody, but also antibody fragments such as Fab, F (ab) '2, Fv, scFv, chimeric antibody (humanized antibody, etc.), and multifunctional antibody. Derivatives such as are included.
  • an antibody that specifically recognizes and binds to the primary antibody as an antigen can be used.
  • Both the primary antibody and the secondary antibody may be polyclonal antibodies, but monoclonal antibodies are preferable from the viewpoint of quantitative stability.
  • the type of animal (immune animal) that produces the antibody is not particularly limited, and may be selected from mice, rats, guinea pigs, rabbits, goats, sheep, and the like as in the conventional case.
  • An immunostaining agent is obtained by dispersing a labeled antibody in which an antibody capable of directly or indirectly binding to a target biological substance and a labeling substance are directly or indirectly bound in an appropriate medium. Will be generated.
  • the primary antibody and the fluorescent substance-accumulated nanoparticles indirectly that is, the antigen-antibody reaction or the avidin-biotin reaction was used.
  • an immunostaining agent in which an antibody and fluorescent nanoparticles are indirectly linked, [primary antibody against the target biological substance] ... [antibody against the primary antibody (secondary antibody)] to [fluorescent nanoparticles (fluorescent nanoparticle) )].
  • “...” indicates that the bond is formed by an antigen-antibody reaction, and the mode of binding indicated by “ ⁇ ” is not particularly limited, and is, for example, covalent bond, ionic bond, hydrogen bond, coordination bond, or physical bond. Examples thereof include adsorption or chemisorption, and may be mediated by a linker molecule if necessary.
  • the secondary antibody-fluorescent substance-accumulated nanoparticle conjugate can be prepared, for example, by using a silane coupling agent which is a compound widely used for binding an inorganic substance and an organic substance.
  • This silane coupling agent is a compound having an alkoxysilyl group that gives a silanol group by hydrolysis at one end of the molecule and a functional group such as a carboxyl group, an amino group, an epoxy group, or an aldehyde group at the other end. It binds to an inorganic substance via the oxygen atom of the silanol group.
  • silane coupling agent having a polyethylene glycol chain for example, PEG-silaneno. SIM6492.7 manufactured by Gelest
  • two or more kinds may be used in combination.
  • a known method can be used for the reaction procedure between the fluorescent substance-accumulated nanoparticles and the silane coupling agent.
  • the obtained silica nanoparticles containing a fluorescent substance are dispersed in pure water, aminolopyrtriethoxysilane is added, and the mixture is reacted at room temperature for 12 hours.
  • silica nanoparticles having a surface modified with an aminopropyl group can be obtained by centrifugation or filtration.
  • the amino group with the carboxyl group in the antibody the antibody can be bound to silica nanoparticles containing a fluorescent substance via an amide bond.
  • a condensing agent such as EDC (1-Ethyl-3- [3-Dimethylaminopropyl] carbodiimide Hydrochloride: manufactured by Pierce) can also be used.
  • a linker compound having a site capable of directly binding to silica nanoparticles containing an organic molecule-modified fluorescent substance and a site capable of binding to a molecular target substance can be used.
  • sulfo-SMCC Sulfosuccinimidyl-4- [N-maleimidomethyl] cyclohexane-1-carboxylate: manufactured by Pierce
  • Pierce having both a site that selectively reacts with an amino group and a site that selectively reacts with a mercapto group.
  • a biological substance recognition site a site that can specifically recognize a biological substance, for example, biotin, avidin, an antibody, etc.
  • the fluorescent substance is either a fluorescent organic dye or a quantum dot.
  • similar procedures can be applied. That is, by impregnating polystyrene nanoparticles having a functional group such as an amino group with quantum dots or a fluorescent organic dye, fluorescent substance-accumulated polystyrene particles having a functional group can be obtained, and thereafter, by using EDC or sulfo-SMCC. , Fluorescent substance-accumulated polystyrene particles to which the antibody is bound are formed.
  • an immunostaining agent in which an antibody and fluorescent nanoparticles are indirectly linked, [primary antibody against a target biological substance] ... [antibody against a primary antibody (secondary antibody)]-[biotin] / [avidin]- [Fluorescent substance (fluorescent substance-accumulated nanoparticles)] (Here, "! indicates that the bond is bound by an antigen-antibody reaction, and "-" is a covalent bond that may be mediated by a linker molecule, if necessary. It indicates that they are bound, and "/" indicates that they are bound by the avidin-biotin reaction).) Examples thereof include a complex consisting of three molecules linked in a manner.
  • biotin-modified secondary antibody for example, a commercially available biotin labeling reagent (kit) is used based on a known method capable of binding biotin to a desired antibody (protein). Can be produced. Further, if a biotin-modified secondary antibody itself in which biotin is bound to a desired antibody in advance is commercially available, it may be used.
  • Fluorescent material-accumulated nanoparticles-avidin conjugate are also produced based on a known method capable of binding avidin to a phosphor, for example, using a commercially available avidin labeling reagent (kit). can do.
  • the avidin in this case may be an improved form such as streptavidin or neutravidin, which has a higher binding force with biotin than avidin.
  • the functional groups of the resin and the functional groups of avidin (protein) are, if necessary, a linker molecule such as PEG having functional groups at both ends of the molecule. It can be combined by means of.
  • a linker molecule such as PEG having functional groups at both ends of the molecule.
  • a linker molecule such as PEG having functional groups at both ends of the molecule.
  • a functional group such as an amino group
  • a monomer having a functional group for example, an epoxy group
  • the functional group itself or a functional group converted from the functional group for example, an amino group produced by reacting aqueous ammonia
  • another functional group can be utilized by utilizing those functional groups.
  • a group can also be introduced.
  • a desired functional group can be introduced by surface modification with a silane coupling agent.
  • an amino group is introduced by using aminopropyltrimethoxysilane. be able to.
  • a thiol group can be introduced by reacting, for example, N-succinimidyl S-acetylthioacetate (SATA) with the amino group of avidin.
  • tissue specimen is a tissue section of an organ collected from a subject (such as a cancer patient) or a cell obtained by culturing cells contained in the tissue collected from the subject.
  • a subject such as a cancer patient
  • three or more organs of a subject are targeted, and lesion cells such as tumor cells (target portion) from each organ and normal cells (target portion) to be compared with the lesion cells are selected. It is collected as a tissue sample.
  • the source of the lesion cells and the normal cells is not limited to the same subject. That is, lesion cells and normal cells may be collected from different subjects.
  • Tissue specimens generally take the form of specimen slides on which tissue sections or cells are placed, as is commonly used when evaluating the expression level of a target biological substance by immunohistochemical staining.
  • the method for preparing the tissue specimen is not particularly limited, and generally, for example, a tissue section collected from a subject is fixed with formalin or the like, dehydrated with alcohol, treated with xylene, and subjected to high-temperature paraffin.
  • a tissue sample prepared by embedding paraffin in it can be obtained by making a section of 3 to 4 ⁇ m, and the sample slide can be obtained by placing the tissue section on a slide glass and drying it. Can be made.
  • the staining method for tissue specimens will be described below.
  • the staining method described below is not limited to tissue sections and can also be applied to cell staining.
  • Specimen preparation step (6.1.1) Deparaffin treatment
  • the section is immersed in a container containing xylene to remove paraffin.
  • the temperature is not particularly limited, but it can be carried out at room temperature.
  • the immersion time is preferably 3 minutes or more and 30 minutes or less. If necessary, xylene may be replaced during immersion.
  • the section is immersed in a container containing ethanol to remove xylene.
  • the temperature is not particularly limited, but it can be carried out at room temperature.
  • the immersion time is preferably 3 minutes or more and 30 minutes or less. If necessary, ethanol may be replaced during immersion.
  • the temperature is not particularly limited, but it can be carried out at room temperature.
  • the immersion time is preferably 3 minutes or more and 30 minutes or less. If necessary, the water may be replaced during immersion.
  • the activation treatment of the target biological substance is carried out according to a known method.
  • the activation conditions are not particularly specified, but the activation solution is 0.01 M citrate buffer (pH 6.0), 1 mM EDTA solution (pH 8.0), 5% urea, and 0.1 M Tris-hydrochloric acid buffer.
  • a liquid or the like can be used.
  • the pH condition is such that a signal is output from the range of pH 2.0 to 13.0 depending on the tissue section to be used and the tissue roughness is such that the signal can be evaluated. Normally, the pH is 6.0 to 8.0, but for special tissue sections, for example, pH 3.0 is also used.
  • an autoclave As the heating device, an autoclave, a microwave, a pressure cooker, a water bath, or the like can be used.
  • the temperature is not particularly limited, but it can be carried out at room temperature.
  • the temperature can be 50 to 130 ° C. and the time can be 5 to 30 minutes.
  • the section after activation treatment is immersed in a container containing PBS and washed.
  • the temperature is not particularly limited, but it can be carried out at room temperature.
  • the immersion time is preferably 3 minutes or more and 30 minutes or less. If necessary, PBS may be replaced during immersion.
  • (6.2) Immunohistochemical Staining Step in order to stain the target biological substance, a solution of the immunostaining agent is placed on a section and reacted with the target biological substance.
  • the solution of the immunostaining agent used in the immunohistochemical staining step may be prepared in advance before this step.
  • the conditions for performing the immunohistochemical staining step are based on the conventional immunohistochemical staining method so that an appropriate signal can be obtained. It can be adjusted as appropriate.
  • the temperature is not particularly limited, but it can be carried out at room temperature.
  • the reaction time is preferably 30 minutes or more and 24 hours or less. It is preferable to drop a known blocking agent such as PBS containing BSA or a surfactant such as Tween 20 before performing the treatment as described above.
  • the immunostaining agent is a complex of [primary antibody (probe)] ... [secondary antibody]-[biotin] / [avidin]-[fluorescent nanoparticles (fluorescent substance-accumulated nanoparticles, etc.)], the first Immersing the tissue sample in the solution of the primary antibody (primary reaction process), then immersing the tissue sample in the solution of the secondary antibody-biotin conjugate (secondary reaction process), and finally according to the present invention.
  • a treatment fluorescence labeling treatment
  • tissue specimen after the immunohistochemical staining step is subjected to treatments such as immobilization / dehydration, permeation, and encapsulation so as to be suitable for observation.
  • the tissue specimen may be immersed in a fixation treatment solution (crosslinking agent such as formalin, paraformaldehyde, glutaaldehyde, acetone, ethanol, methanol).
  • the permeation treatment may be performed by immersing the tissue specimen after the immobilization / dehydration treatment in a permeation solution (xylene or the like).
  • the encapsulation treatment may be performed by immersing the tissue specimen that has undergone the permeation treatment in the encapsulation liquid.
  • the conditions for performing these treatments for example, the temperature and the immersion time when immersing the tissue specimen in a predetermined treatment solution, may be appropriately adjusted so as to obtain an appropriate signal according to the conventional immunostaining method. it can.
  • Morphological Observation Staining Step Apart from the immunohistochemical staining step, morphological observation staining may be performed so that the morphology of cells, tissues, organs, etc. can be observed in a bright field.
  • the morphological observation dyeing step can be performed according to a conventional method. For morphological observation of tissue specimens, staining with eosin, in which cytoplasm, interstitium, various fibers, erythrocytes, and keratinocytes are stained in red to deep red, is standardly used.
  • Staining with hematoxylin in which the cell nucleus, lime, cartilage tissue, bacteria, and mucus are stained in blue to pale blue, is also standardly used (the method of performing these two stainings at the same time is hematoxylin / eosin staining). Known as (HE staining)).
  • staining with a fluorescent dye such as DAPI (4', 6-diamidino-2-phenylindole) that specifically stains the cell nucleus may be performed.
  • DAPI 6-diamidino-2-phenylindole
  • Evaluation method (7.1) Observation / imaging step
  • the microscope image acquisition device 1A is set to a desired magnification, and the target biological substance used in the immunohistochemical staining step is displayed in the same field of view.
  • the tissue specimen is irradiated with excitation light corresponding to each fluorescent substance to be fluorescently labeled, and a fluorescent image due to fluorescence emitted from those fluorescent substances is observed and photographed.
  • the quantification step image processing of a fluorescent image and quantification of the expression level are performed.
  • the quantification step according to the present embodiment corresponds to the acquisition step according to the present invention, and is executed by the control unit 21.
  • the control unit 21 acquires expression information of fluorescently labeled target biological substances of normal cells and abnormal cells in three or more organs. In this embodiment, about 3 to 100 samples of normal cells and about 3 to 100 samples of abnormal cells are used to obtain the above expression information.
  • the control unit 21 measures the fluorescence labeling signal such as the number of bright spots of fluorescence or the emission brightness corresponding to the target biological substance based on the image processing in the information acquisition device 2A for the fluorescent image taken with respect to the target biological substance.
  • the value obtained by quantifying the expression level of each target biological substance in the cell region is acquired as expression information.
  • the number of PID particles corresponding to the number of bright spots is measured, and the value obtained by calculating the number of particles per cell can be used as expression information.
  • the expression information may be a value obtained by calculating the number of particles per unit area of the tissue.
  • Examples of software that can be used for image processing and quantification of expression level include "ImageJ" (open source). By using such image processing software, processing such as extracting bright spots of a predetermined wavelength (color) from a fluorescent image and measuring the number of bright spots having a predetermined brightness or higher is semi-automatically and quickly. Can be done.
  • the size is constant and can be recognized by microscopic observation.
  • a signal whose size is larger than a constant value is judged to be an aggregated bright spot.
  • the bright spots and aggregated bright spots can be semi-automatically and quickly distinguished using software.
  • the display unit 23 displays the list information obtained by digitizing the expression information acquired in the quantification step and displaying the list information, and the evaluation support information including the threshold value indicating a predetermined threshold value. Let me.
  • FIG. 3 is an example showing the evaluation support information displayed on the display unit 23.
  • the list information is a bar-shaped display of the distribution of expression information (number of particles per cell) of normal cells and abnormal cells for each organ.
  • the threshold value information is a linear display of a predetermined threshold value (indicated by a broken line in FIG. 3).
  • the threshold is taken from multiple finalally effective tissue specimens taken before or during preoperative chemotherapy.
  • an ROC curve receiveriver operating characteristic curve
  • PID score mean value of the number of PID particles per cell
  • the threshold is a background (negative control: PID at the time of reaction without a primary antibody, as used in ELISA (Enzyme-Linked ImmunoSorbent Assay), which is a general biological measurement. It is also possible to add 3 times the standard deviation ⁇ to the mean value of the score) (mean value of negative control + 3 ⁇ ).
  • the method of setting the threshold value is not limited to this, and other than this, the threshold value setting method may be set based on the result of comparing the expression information of normal cells and abnormal cells. Further, using AI (Artificial Intelligence), a threshold value may be set by iteratively analyzing a large amount of information and finding a pattern from the information.
  • AI Artificial Intelligence
  • a threshold value may be set by iteratively analyzing a large amount of information and finding a pattern from the information.
  • the drug discovery support method used in the present invention is used for adjusting the sensitivity of the drug after setting the threshold value from the information obtained from the actual tissue sample, or the threshold value is determined from the list information obtained by quantifying the expression information.
  • it can be widely used for drug discovery creation, such as by using it as a method for determining the sensitivity of a drug.
  • Pattern (1) is an example showing the case where the maximum value of normal cells ⁇ threshold value and the minimum value of abnormal cells> threshold value.
  • Pattern (2) is an example showing the case where the minimum value of normal cells> the threshold value and the minimum value of abnormal cells> the threshold value. In the case of pattern (2), it is necessary to adjust the sensitivity to the drug, and it can be inferred that the drug is suitable for this organ.
  • Pattern (3) is an example showing the case where the minimum value of normal cells> the threshold value and the maximum value of abnormal cells ⁇ threshold value. In the case of pattern (3), it can be inferred that it is inappropriate for this organ. That is, when this happens, it can be determined that it is bad for the organ.
  • Pattern (4) is an example showing the case where the maximum value of normal cells ⁇ threshold value and the maximum value of abnormal cells ⁇ threshold value. In the case of pattern (4), it can be inferred that the sensitivity needs to be adjusted.
  • the evaluation support information of the present embodiment lists the expression information of a plurality of organs and displays them together with the threshold value, it enables the user to visually grasp the sensitivity and the suitable organ at a glance. Is. Drug discovery is performed according to the threshold value. Further, on the display unit 23, the position of the threshold information can be adjusted by an instruction operation via the operation unit 22 of the user. This makes it possible to quickly and easily infer the ideal position for a plurality of organs.
  • the expression information values of normal cells and abnormal cells for the liver, kidney, large intestine, and small intestine are displayed as list information.
  • the threshold information L1 when the threshold information L1 is shown, it can be inferred that the liver, kidney, and large intestine are target candidates and are inappropriate for the small intestine.
  • the threshold value information L2 when the threshold value information L2 is shown, it is considered to be effective for the liver and the large intestine, but there is a concern about side effects on the kidney and the small intestine.
  • the threshold information L3 is shown in FIG. 3, the effect can be expected in any of the liver, kidney, large intestine, and small intestine, but side effects are a concern.
  • the threshold value and the expression information value of the cell are compared, and when a certain ratio of the expression information value displayed in a rod shape is larger than the threshold value, it can be judged to be effective. Since a certain percentage that can be judged to be effective differs depending on the antigen, it is judged for each antigen.
  • expression information may be acquired from a more localized structure (Golgi apparatus, endoplasmic reticulum, mitochondria, cytoplasm, cell membrane, cell nucleus, etc.).
  • Golgi apparatus, endoplasmic reticulum, mitochondria are extracted from the fluorescent image of the abnormal cell, and the expression information of the target biological substance (HER2 protein or HER2 mRNA) is acquired from the extracted image. ..
  • the target biological substance HER2 protein or HER2 mRNA
  • protein and mRNA can be detected on the same tissue section, it is possible to identify a subject or an organ in which the target mRNA is expressed but the protein is not expressed.
  • the drug discovery support method of the present embodiment is fluorescently labeled with abnormal cells (target part) in a plurality of organs (biological sites) and normal cells (target part) to be compared with the abnormal cells.
  • the acquisition process for acquiring the expression information of the target biological substance, the list information obtained by digitizing the expression information of each part acquired in the acquisition process, and the threshold information indicating a predetermined threshold are displayed on the display unit. It has a process.
  • the display step displays list information in which the expression information of each part is arranged in a bar shape and threshold information in which the threshold value is displayed in a straight line. Therefore, the value indicating the expression information of the abnormal cells and the normal cells of a plurality of organs and the threshold value can be recognized at a glance, and the sensitivity of the drug and the suitable organ can be quickly and accurately determined.
  • a threshold value setting step of setting a threshold value based on background data representing a background component included in the expression information of each part.
  • the threshold value can be set based on the background data.
  • the acquisition step acquires the expression information of the fluorescently labeled target biological substance of the abnormal cells and the prenormal cells in the three or more organs. Therefore, the list information for the three or more organs is obtained. And by comparing the threshold information, it is more useful in improving the efficiency of the drug discovery stage.
  • the expression information is acquired from three or more organs of the subject, but the expression information may be acquired from at least two organs.
  • the present invention can be used to quickly and accurately determine the sensitivity of a drug and a suitable biological site.
  • Pathological diagnosis support system 1A Microscopic image acquisition device 2A Information acquisition device 21 Control unit (acquisition means, display control means) 22 Operation unit 23 Display unit 24 Communication I / F 25 Memory

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Sustainable Development (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne un procédé d'aide à la découverte de médicament, ledit procédé comprenant les étapes suivantes : l'acquisition des données d'expression d'un organisme vivant cible qui est marqué par fluorescence au niveau de cellules anormales (parties cibles) et de cellules normales (parties témoin), lesdites cellules normales devant être comparées aux cellules anormales, dans de multiples organes (régions de corps); et l'affichage des données de liste, dans lesquelles les données d'expression des parties individuelles acquises dans l'étape d'acquisition sont quantifiées et listées, et des données de seuil, dans lesquelles des seuils prédéfinis sont indiqués, sur une unité d'affichage.
PCT/JP2020/031480 2019-08-29 2020-08-20 Procédé d'aide à la découverte de médicament, dispositif d'aide à la découverte de médicament et programme WO2021039592A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021542816A JPWO2021039592A1 (fr) 2019-08-29 2020-08-20

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019-156236 2019-08-29
JP2019156236 2019-08-29

Publications (1)

Publication Number Publication Date
WO2021039592A1 true WO2021039592A1 (fr) 2021-03-04

Family

ID=74685516

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/031480 WO2021039592A1 (fr) 2019-08-29 2020-08-20 Procédé d'aide à la découverte de médicament, dispositif d'aide à la découverte de médicament et programme

Country Status (2)

Country Link
JP (1) JPWO2021039592A1 (fr)
WO (1) WO2021039592A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003242154A (ja) * 2002-02-18 2003-08-29 Celestar Lexico-Sciences Inc 遺伝子発現情報管理装置、遺伝子発現情報管理方法、プログラム、および、記録媒体
JP2008101968A (ja) * 2006-10-18 2008-05-01 Yokogawa Electric Corp 創薬スクリーニング装置及び創薬スクリーニング方法
WO2009048039A1 (fr) * 2007-10-12 2009-04-16 Konica Minolta Medical & Graphic, Inc. Procédé d'imagerie de molécule/cellule et nanoparticules semi-conductrices
JP2010169678A (ja) * 2008-12-25 2010-08-05 Canon Inc 生物試料用標識剤並びに該標識剤を用いた標識方法及びスクリーニング方法
JP2011509246A (ja) * 2007-12-26 2011-03-24 ヴァクシネックス， インコーポレイテッド 抗ｃ３５抗体併用療法および方法
WO2012029269A1 (fr) * 2010-09-02 2012-03-08 国立大学法人東北大学 Méthode de détermination de l'apparition d'un cancer ou du risque d'apparition d'un cancer
JP2012256175A (ja) * 2011-06-08 2012-12-27 Yokogawa Electric Corp 画像処理方法、画像処理装置およびこれらを用いた創薬支援装置

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003242154A (ja) * 2002-02-18 2003-08-29 Celestar Lexico-Sciences Inc 遺伝子発現情報管理装置、遺伝子発現情報管理方法、プログラム、および、記録媒体
JP2008101968A (ja) * 2006-10-18 2008-05-01 Yokogawa Electric Corp 創薬スクリーニング装置及び創薬スクリーニング方法
WO2009048039A1 (fr) * 2007-10-12 2009-04-16 Konica Minolta Medical & Graphic, Inc. Procédé d'imagerie de molécule/cellule et nanoparticules semi-conductrices
JP2011509246A (ja) * 2007-12-26 2011-03-24 ヴァクシネックス， インコーポレイテッド 抗ｃ３５抗体併用療法および方法
JP2010169678A (ja) * 2008-12-25 2010-08-05 Canon Inc 生物試料用標識剤並びに該標識剤を用いた標識方法及びスクリーニング方法
WO2012029269A1 (fr) * 2010-09-02 2012-03-08 国立大学法人東北大学 Méthode de détermination de l'apparition d'un cancer ou du risque d'apparition d'un cancer
JP2012256175A (ja) * 2011-06-08 2012-12-27 Yokogawa Electric Corp 画像処理方法、画像処理装置およびこれらを用いた創薬支援装置

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GODA, HIDEKI ET AL.: "HSTT (High Sensitive Tissue Testing) Technology", 2 HSTT(HIGH SENSITIVE TISSUE TESTING),KONICA MINOLTA TECHNOLOGY REPORT, vol. 14, 2017, pages 14 - 17 *

Also Published As

Publication number Publication date
JPWO2021039592A1 (fr) 2021-03-04

Similar Documents

Publication Publication Date Title
EP3124969B1 (fr) Procédé d'analyse quantitative de matériau biologique sur la base d'une immunocoloration à antigènes multiples
JP5906623B2 (ja) 生体物質発現レベル評価システム
AU2010206657A1 (en) Apparatus and methods for detecting inflammation using quantum dots
JP6960224B2 (ja) 生体物質定量方法、病理診断支援システム及びプログラム
JP6597316B2 (ja) 画像処理装置及びプログラム
US10656092B2 (en) Biological material quantifying method, image processing device, pathological diagnosis support system and recording medium
JP5887823B2 (ja) 組織評価方法
WO2015146938A1 (fr) Procédé d'évaluation de tissu, dispositif de traitement d'image, système d'aide au diagnostic pathologique, et programme
WO2017014196A1 (fr) Procédé d'analyse et système d'analyse de substances biologiques cibles
US20180156699A1 (en) Pathological Specimen, Method For Producing Pathological Specimen, And Method For Acquiring Fluorescence Image
WO2017175523A1 (fr) Procédé d'immunocoloration fluorescente
JP5863057B2 (ja) 組織評価方法
WO2021039592A1 (fr) Procédé d'aide à la découverte de médicament, dispositif d'aide à la découverte de médicament et programme
US20200165666A1 (en) Diluent for fluorescent nano particles, kit for immunofluorescent staining which utilizes same, solution for immunofluorescent staining, immunofluorescent staining method, and gene staining method
WO2020166469A1 (fr) Méthode de fourniture d'informations, dispositif de fourniture d'informations et programme
JP6702339B2 (ja) 画像処理装置及びプログラム
JP7160047B2 (ja) 生体物質定量方法、画像処理装置及びプログラム
WO2020050373A1 (fr) Procédé d'acquisition d'informations, dispositif d'acquisition d'informations et programme
WO2021192910A1 (fr) Procédé et dispositif de génération d'images et programme
JPWO2019078230A1 (ja) 生体物質定量方法、画像処理装置、病理診断支援システム及びプログラム

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20857321

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021542816

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20857321

Country of ref document: EP

Kind code of ref document: A1